Fusion Pharmaceuticals

Full Presentation Download FGFR3 Targeted Alpha Therapeutic [225 Ac]-FPI-1966 Induces Regression in Preclinical Bladder Xenograft Model

Full Poster Download FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy

The page describes Fusion Pharmaceuticals’ pipeline of targeted alpha therapeutics and related technology.

Full Presentation Download NTSR1 Targeted Alpha Therapeutic [225Ac]-FPI-2059 Induces Regression in Preclinical Colorectal Xenograft Model

The page describes IGF-1R as a transmembrane protein overexpressed in solid tumors, including non-small cell types.

Research combines IGF-1R targeted alpha therapy with immune checkpoint inhibitors to treat syngeneic models.

Research combines IGF-1R targeted alpha therapy with immune checkpoint inhibitors to treat colorectal cancer.

Fusion Pharmaceuticals develops next-generation radiopharmaceuticals for precision oncology.

Fusion Pharmaceuticals will present research on targeted alpha-particle radiotherapeutics for cancer.

The evolution of radiopharmaceuticals. Fusion Pharma is using targeted alpha therapeutics to improve the safety of radiopharmaceuticals.

AstraZeneca has acquired Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company specializing in next-generation radioconjugates (RCs). The deal advances AstraZeneca’s goal of replacing chemotherapy and radiotherapy with targeted cancer treatments. Fusion’s technology focuses on precision therapies designed to improve patient outcomes.

Jun 2024AstraZenecaNews article

Fusion Pharmaceuticals secures final court approval for its statutory plan of arrangement under Canadian corporate law, enabling a subsidiary sale to AstraZeneca. The clinical-stage oncology company specializes in next-generation radioconjugates for precision cancer treatments. The deal follows a previously announced transaction involving a wholly-owned subsidiary.

May 2024PR NewswireNews article

AstraZeneca acquires Fusion Pharmaceuticals for $2 billion, integrating the company into its cancer-focused business unit. The deal expands AstraZeneca’s portfolio in the growing radiopharmaceuticals sector, targeting advanced cancer therapies. Both companies specialize in developing targeted radiation treatments for oncology.

Mar 2024Fierce BiotechNews article

AstraZeneca acquires Fusion Pharmaceuticals, a radiopharmaceutical company, in a $2 billion deal. This marks AstraZeneca’s second billion-dollar acquisition in under a week. The move expands AstraZeneca’s focus on radiopharma therapies, a growing area in oncology treatments.

Mar 2024Chemical & Engineering NewsNews article